---
document_datetime: 2025-07-18 16:28:28
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ztalmy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ztalmy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.646823
conversion_datetime: 2025-12-24 17:15:09.906518
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ZTALMY

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                       | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / EMA/VR/0000281558 | This was an application for a group of variations. | 18/07/2025                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                                         | batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when   |            |            |                        |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000265555 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Marinus Pharmaceuticals Emerald Limited to Immedica Pharma AB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 07/05/2025 | 02/06/2025 | SmPC, Labelling and PL |
| Variation type II / EMA/VR/0000252415                   | B.I ACTIVE SUBSTANCE - B.I.z Substantial updates to Mod. 3.2.S or the ASMF - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/04/2025 | N/A        |                        |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000245802   | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted To split MEA005 into two separate studies. GNX and M2 Transgenic Mouse Carcinogenicity Study A 26- week Oral Gavage Carcinogenicity Study of Ganaxolone (GNX) and M2 (Ganaxolone Metabolite) in Hemizygous CByB6F1-Tg(HRAS)2Jic Mice, with the original due date of Q1 2025 and M2 Transgenic Mouse Carcinogenicity Study A 26-week Oral Gavage Carcinogenicity Study of M2 (Ganaxolone Metabolite) in Hemizygous CByB6F1-Tg(HRAS)2Jic Mice with an extended due date of Q4 2026.   | 05/03/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|